Improving HIV Prevention and Treatment Outcomes Among HIV Infected Persons by Integrating Community Pharmacists and Clinical Sites into a Model of Patient centered HIV Care
Opportunity Identification: CDC RFA PS13 1315
Opportunity summary
The announcement explains that today’s HIV care is increasingly complex because patients are living longer and are more likely to experience co-morbid conditions alongside HIV. Providers must manage long-term ART, monitor and address medication side effects, and prevent or resolve clinically significant drug-drug interactions. At the same time, people living with HIV face an increased risk of age-associated, non-AIDS-related illness and mortality, which means clinical teams must pay attention not only to viral suppression but also to whole-person health needs over time. In this context, the grant opportunity proposes that community pharmacists can play a more integrated role with clinical sites to strengthen medication management and continuity of care, reducing gaps that can occur when treatment regimens are complicated and patients interact with multiple parts of the healthcare system.
In practical terms, the opportunity supports a model of patient-centered HIV care that formally connects community-based pharmacy services with HIV clinical care settings. Community pharmacists are positioned to contribute to adherence support, medication counseling, identification of potential interactions (including with medications for other chronic conditions), monitoring issues related to side effects and tolerability, and reinforcing prevention-related messages and behaviors as part of routine medication touchpoints. By tying pharmacists more closely to clinical sites, the model aims to improve communication, coordination, and follow-through, which are essential for maintaining viral suppression and preventing avoidable complications. The overall emphasis is on improving HIV-related outcomes by strengthening the care team around the patient, rather than leaving medication-related challenges to be addressed only during periodic clinic visits.
The funding mechanism is a cooperative agreement, which generally indicates substantial federal involvement or collaboration in the funded project’s implementation compared with a standard grant. The total estimated funding amount listed is $2.3 million, with an award ceiling of $2.3 million, and the CDC expected to make one award under this announcement. There is no cost-sharing or matching requirement. The program is associated with CFDA number 93.941, described as HIV Demonstration, Research, Public and Professional Education Projects, suggesting the work is intended to demonstrate and operationalize an improved service model and generate practical lessons that can inform broader practice.
Eligibility is broad and includes many types of organizations that could realistically build partnerships between pharmacists and clinical providers. Eligible applicants include state and local governments and their agents, tribal governments and tribal organizations, urban Indian health organizations, colleges and universities, hospitals, community-based and faith-based organizations, research institutions (for activities considered non-research under the award), nonprofit organizations with or without 501(c)(3) status, and certain for-profit entities (other than small businesses), as well as small, minority-, and women-owned businesses. This wide eligibility reflects the fact that effective HIV care coordination can be led by public health departments, healthcare systems, academic entities, or community organizations, depending on local infrastructure and patient needs.
Key administrative details from the listing include a posted date of April 1, 2013, with an original and current closing date of May 15, 2013, and an archive date of June 14, 2013. The CDC Procurement and Grants Office is listed as the contact point for accessing the full announcement if needed. Overall, the opportunity is designed to support a single, well-resourced demonstration that operationalizes a patient-centered HIV care approach by deliberately integrating community pharmacists with clinical HIV care sites, addressing the modern realities of long-term HIV management: adherence challenges, complex drug regimens, co-morbidities, side effects, interactions, and aging-related health risks.
Frequently asked questions
What is the purpose of this CDC funding opportunity?
The purpose is to improve HIV prevention and treatment outcomes for people living with HIV by integrating community pharmacists and clinical care sites into a patient-centered model of HIV care. The model is designed to strengthen medication management and continuity of care in response to the modern realities of long-term HIV treatment.
What is the Funding Opportunity Number (FON) for this announcement?
The Funding Opportunity Number is CDC RFA PS13-1315.
Which federal agency is offering this opportunity?
This opportunity is issued by the Centers for Disease Control and Prevention (CDC).
What type of funding mechanism is being used?
The funding mechanism is a discretionary cooperative agreement, which generally indicates substantial federal involvement or collaboration in the funded project compared with a standard grant.
How much funding is available under this opportunity?
The total estimated funding amount is $2.3 million, and the award ceiling is also $2.3 million.
How many awards does CDC expect to make?
CDC expected to make one award under this announcement.
Is cost-sharing or matching required?
No. The opportunity states there is no cost-sharing or matching requirement.
What is the core idea behind integrating community pharmacists into HIV care?
HIV care has shifted over the past two decades from an acute, life-threatening illness managed primarily by specialists to a chronic, manageable condition for many patients due to advances in antiretroviral therapy (ART). That success has introduced new care coordination challenges, including long-term medication management, co-morbidities, side effects, and drug-drug interactions. Community pharmacists are positioned to support patients more routinely and help clinical sites maintain strong medication-related follow-through between clinic visits.
What patient needs is this model intended to address?
The model is intended to address challenges associated with long-term ART and chronic HIV management, including adherence support, monitoring and addressing side effects and tolerability, preventing or resolving clinically significant drug-drug interactions, and supporting whole-person health needs as people with HIV live longer and face age-associated, non-AIDS-related illness and mortality risks.
What roles can community pharmacists play in this patient-centered HIV care model?
As described in the announcement, community pharmacists can contribute by supporting adherence, providing medication counseling, identifying potential drug-drug interactions (including interactions involving medications for other chronic conditions), monitoring issues related to side effects and tolerability, and reinforcing prevention-related messages and behaviors during routine medication touchpoints.
How does the model improve communication and coordination between pharmacy and clinical care?
The opportunity supports formally connecting community-based pharmacy services with HIV clinical care settings. By tying pharmacists more closely to clinical sites, the model aims to improve communication, coordination, and follow-through to reduce gaps that can occur when regimens are complicated and patients interact with multiple parts of the healthcare system.
Who is the intended population served by this project?
The intended population is people living with HIV, with an emphasis on improving prevention and treatment outcomes through better coordinated, patient-centered HIV care.
What outcomes is the project trying to improve?
The opportunity emphasizes improving HIV-related outcomes by strengthening the care team around the patient, supporting continuity of care, and addressing medication-related challenges that can affect viral suppression and contribute to avoidable complications.
What is the CFDA number associated with this program?
The program is associated with CFDA number 93.941, described as HIV Demonstration, Research, Public and Professional Education Projects.
Does the opportunity indicate whether the work is meant to be a demonstration project?
Yes. The CFDA description and the announcement framing indicate the work is intended to demonstrate and operationalize an improved service model and generate practical lessons that can inform broader practice.
Who is eligible to apply for this funding?
Eligibility is broad and includes: state and local governments and their agents; tribal governments and tribal organizations; urban Indian health organizations; colleges and universities; hospitals; community-based and faith-based organizations; research institutions (for activities considered non-research under the award); nonprofit organizations with or without 501(c)(3) status; certain for-profit entities (other than small businesses); and small, minority-, and women-owned businesses.
Can nonprofit organizations without 501(c)(3) status apply?
Yes. The eligibility list includes nonprofit organizations with or without 501(c)(3) status.
Are for-profit organizations eligible to apply?
Yes, certain for-profit entities (other than small businesses) are included in the eligibility list, and the listing also mentions small, minority-, and women-owned businesses.
What are the key dates for this funding opportunity?
The posted date is April 1, 2013. The original and current closing date is May 15, 2013. The archive date is June 14, 2013.
Where can applicants find the full announcement or get official administrative guidance?
The CDC Procurement and Grants Office is listed as the contact point for accessing the full announcement if needed.
Why does the announcement emphasize co-morbidities and aging-related risks?
The announcement explains that as people with HIV live longer, they are more likely to experience co-morbid conditions alongside HIV and face increased risk of age-associated, non-AIDS-related illness and mortality. This increases the complexity of care and makes coordinated, long-term medication management and whole-person care more important.
How is this model different from a traditional specialist-centered HIV care approach?
The traditional approach often relies heavily on periodic clinic visits with specialists. This opportunity emphasizes a broader, coordinated support structure by integrating community pharmacists with clinical HIV care sites, aiming to address medication-related issues and adherence needs more continuously as part of routine pharmacy interactions.
What is the main strategy described for reducing gaps in HIV care?
The main strategy is strengthening the care team around the patient by deliberately integrating community pharmacists with HIV clinical care sites to improve coordination, communication, and follow-through on medication management and related support.
Questions about this opportunity?
Contact USGrants.org for help with this listing or similar funding opportunities.
Contact USGrants.orgRelated funding listings
Applicants who have applied for this opportunity (CDC RFA PS13 1315) also looked into and applied for these: